All articles by Vidya Sagar Maddela

Vidya Sagar Maddela

Biogen partners with Stoke to develop treatment for rare brain disorder

Stoke Therapeutics will receive $165m in upfront payment and is eligible to receive up to $385m in development and commercial milestone payments, along with tiered on potential net sales in the Biogen territory

Cellistic rolls out Allo Chassis platform for cell therapy development

Cellistic developed the Allo Chassis platform using its expertise in iPSCs, including T-cell-based treatments, under current Good Manufacturing Practice (cGMP) standards, to enhance global access to cell therapy

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for GOMEKLI (mirdametinib), Manufactured By SpringWorks Therapeutics

Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers

Sanofi secures FDA approval for Novolog biosimilar Merilog

Merilog is a rapid-acting human insulin analogue that works to reduce mealtime blood sugar spikes to improve control of blood sugar in people with diabetes

Zoetis Receives Conditional License from USDA for Avian Influenza Vaccine, H5N2 Subtype, Killed Virus

Zoetis is committed to supporting poultry producers with scientific solutions for Highly Pathogenic Avian Influenza (HPAI)

CSL secures EC approval for Andembry to prevent HAE attacks

EC indicated Andembry, a novel Factor XIIa-inhibitory monoclonal antibody (anti-FXIIa mAb), to prevent the attacks of HAE in adult and adolescent patients, aged 12 years and above

Ensoma Receives Rare Pediatric Disease and Orphan Drug Designations for EN-374 for Treatment of Chronic Granulomatous Disease

In vivo HSC-directed therapy advancing to IND filing in H1 2025 for treatment of X-linked chronic granulomatous disease (X-CGD)

AbbVie partners with Xilio to develop tumour-activated immunotherapies

Under the terms of the agreement, the two companies will develop novel tumour-activated, antibody-based immunotherapies, including masked T-cell engagers, using Xilio’s technology

OnCusp Therapeutics Receives FDA Fast Track Designation for CUSP06 for the Treatment of Platinum-Resistant Ovarian Cancer

The ongoing Phase 1 multicenter study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of CUSP06 in adults with platinum-refractory/resistant ovarian cancer and other advanced solid tumors (CUSP06-1001)

Vertex reports 6% decline in Q4 2024 net income to $913m

The US biopharmaceutical company reported net revenues of $2.91bn for Q4 2024, a 16% rise compared to $2.51bn for the same quarter in 2023, and a 10% increase compared to $2.77bn for Q3 2024